Literature DB >> 22307573

The -258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH.

Maya Y Peltsverger1, Peter W Butler, Anna Teresa Alberobello, Sheila Smith, Yanina Guevara, Ornella M Dubaz, Javier A Luzon, Joyce Linderman, Francesco S Celi.   

Abstract

OBJECTIVE: Type 2 deiodinase gene (DIO2) polymorphisms have been associated with changes in pituitary-thyroid axis homeostasis. The -258A/G (SNP rs12885300) polymorphism has been associated with increased enzymatic activity, but data are conflicting. To characterize the effects of -258A/G polymorphism on intrathyroidal thyroxine (T(4)) to triiodothyronine (T(3)) conversion and thyroid hormone (TH) secretion pattern, we studied the effects of acute, TRH-mediated, TSH stimulation of the thyroid gland.
DESIGN: Retrospective analysis.
METHODS: The TH secretion in response to 500  μg i.v. TRH injection was studied in 45 healthy volunteers.
RESULTS: Twenty-six subjects (16 females and ten males, 32.8 ± 10.4 years) were homozygous for the ancestral (-258A/A) allele and 19 (11 females and eight males, 31.1 ± 10.9 years) were carriers of the (-258G/x) variant. While no differences in the peak TSH and T(3) levels were observed, carriers of the -258G/x allele showed a blunted rise in free T(4) (FT(4); P<0.01). The -258G/x92Thr/Thr haplotype, compared with the other groups, had lower TSH values at 60  min (P<0.03). No differences were observed between genotypes in baseline TH levels.
CONCLUSIONS: The -258G/x DIO2 polymorphism variant is associated with a decreased rate of acute TSH-stimulated FT(4) secretion with a normal T(3) release from the thyroid gland consistent with a shift in the reaction equilibrium toward the product. These data indicate that the -258G DIO2 polymorphism causes changes in the pattern of hormone secretion. These findings are a proof of concept that common polymorphisms in DIO2 can subtly affect the circulating levels of TH and might modulate the TH homeostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307573      PMCID: PMC3509195          DOI: 10.1530/EJE-11-1073

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  26 in total

1.  The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study.

Authors:  Peter W Butler; Sheila M Smith; Joyce D Linderman; Robert J Brychta; Anna Teresa Alberobello; Ornella M Dubaz; Javier A Luzon; Monica C Skarulis; Craig S Cochran; Robert A Wesley; Frank Pucino; Francesco Saverio Celi
Journal:  Thyroid       Date:  2010-11-07       Impact factor: 6.568

2.  Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease.

Authors:  Stig Andersen; Klaus Michael Pedersen; Niels Henrik Bruun; Peter Laurberg
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

3.  Characterization of the 5'-flanking and 5'-untranslated regions of the cyclic adenosine 3',5'-monophosphate-responsive human type 2 iodothyronine deiodinase gene.

Authors:  T Bartha; S W Kim; D Salvatore; B Gereben; H M Tu; J W Harney; P Rudas; P R Larsen
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

4.  Expression and regulation of type II iodothyronine deiodinase in human thyroid gland.

Authors:  M Murakami; O Araki; Y Hosoi; Y Kamiya; T Morimura; T Ogiwara; H Mizuma; M Mori
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

5.  Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects.

Authors:  Niels Grarup; Mette K Andersen; Camilla H Andreasen; Anders Albrechtsen; Knut Borch-Johnsen; Torben Jørgensen; Johan Auwerx; Ole Schmitz; Torben Hansen; Oluf Pedersen
Journal:  J Clin Endocrinol Metab       Date:  2006-10-31       Impact factor: 5.958

6.  Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects.

Authors:  Robin P Peeters; Hans van Toor; Willem Klootwijk; Yolanda B de Rijke; George G J M Kuiper; Andre G Uitterlinden; Theo J Visser
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

7.  Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.

Authors:  Massimo Torlontano; Cosimo Durante; Isabella Torrente; Umberto Crocetti; Giovanni Augello; Giuseppe Ronga; Teresa Montesano; Laura Travascio; Antonella Verrienti; Rocco Bruno; Stefano Santini; Palmina D'Arcangelo; Bruno Dallapiccola; Sebastiano Filetti; Vincenzo Trischitta
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

8.  Thyroid hormone receptors and type I iodothyronine 5'-deiodinase activity of human thyroid toxic adenomas and benign cold nodules.

Authors:  J Brtko; J Bobálová; J Podoba; C Schmutzler; J Köhrle
Journal:  Exp Clin Endocrinol Diabetes       Date:  2002-06       Impact factor: 2.949

9.  Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element.

Authors:  G Canettieri; F S Celi; G Baccheschi; L Salvatori; M Andreoli; M Centanni
Journal:  Endocrinology       Date:  2000-05       Impact factor: 4.736

10.  Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor.

Authors:  Daniela Mentuccia; Laura Proietti-Pannunzi; Keith Tanner; Vincenzo Bacci; Toni I Pollin; Eric T Poehlman; Alan R Shuldiner; Francesco S Celi
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

View more
  8 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

2.  Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment - Data Using a Blind, Randomized, Clinical Study.

Authors:  Allan Carlé; Jens Faber; Rudi Steffensen; Peter Laurberg; Birte Nygaard
Journal:  Eur Thyroid J       Date:  2017-04-24

3.  Targeting the right population for T3 + T4 combined therapy: where are we now and where to next?

Authors:  Tommaso Porcelli; Domenico Salvatore
Journal:  Endocrine       Date:  2020-06-22       Impact factor: 3.633

4.  Effect of Functionally Significant Deiodinase Single Nucleotide Polymorphisms on Drinking Behavior in Alcohol Dependence: An Exploratory Investigation.

Authors:  Mary R Lee; Melanie L Schwandt; Jared W Bollinger; Alexandra A Dias; Emily N Oot; David Goldman; Colin A Hodgkinson; Lorenzo Leggio
Journal:  Alcohol Clin Exp Res       Date:  2015-07-24       Impact factor: 3.455

Review 5.  Mechanisms of thyroid hormone action.

Authors:  Gregory A Brent
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

6.  Study of Deiodinase Type 2 Polymorphisms in Graves' Disease and Ophthalmopathy in a Swedish Population.

Authors:  Bushra Shahida; Tereza Planck; Peter Åsman; Mikael Lantz
Journal:  Eur Thyroid J       Date:  2018-07-20

7.  A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population.

Authors:  Maha M AlRasheed; Ashwaq AlAnzi; Rawan AlShalhoub; Norah Abanmy; Dana Bakheet
Journal:  Saudi Pharm J       Date:  2019-05-21       Impact factor: 4.330

8.  Combination Therapy for Hypothyroidism: Rationale, Therapeutic Goals, and Design.

Authors:  Ritu Madan; Francesco S Celi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-08       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.